亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整的填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Evaluation of the T-Cell Metabolic State of Starting Material and Manufactured CAR T Cell Products and Clinical Outcome of CAR T-Cell Therapy for Large B Cell Lymphoma

嵌合抗原受体 医学 细胞疗法 淋巴瘤 T细胞 CD19 内科学 细胞 流式细胞术 肿瘤科 癌症研究 癌症 免疫学 生物 免疫疗法 免疫系统 遗传学
作者
Chaja F. Jacobs,Helga Simon‐Molas,Gaspard Cretenet,Miriam V. Gutschow,Amy M. Chattin,Garrett Collett,Lucrezia Colonna,Fleur S. Peters,Arnon P. Kater
出处
期刊:Blood [American Society of Hematology]
卷期号:142 (Supplement 1): 3456-3456
标识
DOI:10.1182/blood-2023-188577
摘要

Background Although chimeric antigen receptor (CAR)-T cells are a viable treatment option for patients with relapsed or refractory (r/r) aggressive B-cell lymphomas, more than half of patients experience relapse within the first two years after product infusion. Successful autologous cell-based anti-cancer therapies require persistence of effector cells, features that highly depend on complex metabolic processes. We earlier demonstrated in chronic lymphocytic leukemia, that expansion and persistence of CD19-CAR T-cell infusion in vivo was correlated with increased mitochondrial mass and enhanced biogenesis(van Bruggen et al, Blood 2019). Metabolic features might therefore serve as early biomarker tools to predict efficacy and outcome of CAR T-cell therapy and might allow therapeutic targeting but did was never studied in a prospective clinical trial. Aims Perform extensive phenotyping and state-of-the-art metabolic state analyses of T cells prior and post CAR T cell production and investigate correlations with clinical outcomes and patient characteristics. Methods Samples were obtained from large B cell lymphoma (LBCL) patients that were part of the TRANSCEND-NHL-001 trial (NCT02631044, Abramson et al, Lancet 2020).Thirty-two patients with r/r B-cell lymphoma who received CAR-T cell treatment lisocabtagene maraleucel (16 responders (R) and 16 non-responders (NR)) were included in our analyses and (metabolically) analyzed by flow cytometry and extracellular flux analysis. Metabolic phenotyping was performed on 53 samples at baseline and 44 samples after an in vitro stimulation. Extracellular flux analysis was done on 14 DP samples. The cohort was split evenly between Responders and Non-responders, and balanced for a score calculated taking key clinical baseline characteristics that were found to be associated with response into account (NCT02631044, Abramson et al, Lancet 2020). Both T cells obtained at time of leukopheresis (starting material (SMAT)) and CAR-T drug products (DP), (following transduction of a CD19-targeted CAR T cell product with a defined CD4 and CD8 composition bearing a 4-1BB costimulatory domain and expansion) were analyzed directly after thawing and after stimulation with anti-CAR-antibody in case of CDP, or αCD3/αCD28 antibodies for SMAT samples. Patients consented to these studies and researchers were blinded for clinical outcomes at time of analysis. Results We found that the baseline clinical factors that associate with clinical response are related to specific metabolic cellular phenotypes, both in SMAT and DP, and with and without T cell stimulation. SMAT samples from patients with higher baseline scores show signs of an increased exhausted phenotype with regards to cellular ROS and exhaustion marker expression, whilst a more plentiful memory-like phenotype was seen in patients with a lower baseline score. When clustering by clinical response status, analysis of glucose and fatty-acid uptake, neutral lipid content, cellular ROS, mitochondrial mass and potential and flux data showed that responders, in both SMAT and DP samples, have an all-round increased metabolic activity upon αCD3/αCD28 or CAR T-receptor triggering, respectively, when compared to non-responders (Figure 1A). Furthermore, responding patients show enrichment of CD27 expression in the SMAT material, indicating a more abundant memory phenotype. Summary/Conclusions This is the first evidence of an association between a specific immune-metabolic phenotype of (CAR-) T cells and outcome of CAR-T cell therapy in patients with relapsed/refractory LBCL. More specifically, a higher abundance of memory phenotypes, metabolic activity and mitochondrial biogenesis of both harvested T cells and CAR-T product associates with improved clinical response. Combining metabolic, phenotypical and clinical characteristics and biomarkers of patient T cells (both pre- or post-production) shows the importance of the metabolic phenotype and fitness of T cell starting material, underlying the importance of early line CAR T therapy following diagnosis.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
科研通AI2S应助SDNUDRUG采纳,获得10
20秒前
小王完成签到 ,获得积分10
59秒前
充电宝应助泡面小猪采纳,获得10
1分钟前
1分钟前
lcs完成签到,获得积分10
1分钟前
xiuxiuzhang完成签到 ,获得积分10
1分钟前
CodeCraft应助科研通管家采纳,获得10
1分钟前
1分钟前
呃呃诶完成签到,获得积分10
1分钟前
1分钟前
FashionBoy应助秋刀鱼不过期采纳,获得10
2分钟前
2分钟前
橙花完成签到 ,获得积分10
2分钟前
lalala大鸭梨关注了科研通微信公众号
2分钟前
oleskarabach发布了新的文献求助10
2分钟前
包容新蕾完成签到 ,获得积分10
3分钟前
安静的瑾瑜完成签到 ,获得积分10
3分钟前
3分钟前
田様应助科研通管家采纳,获得10
3分钟前
机灵自中发布了新的文献求助10
3分钟前
彭于晏应助对流域采纳,获得10
4分钟前
机灵自中完成签到,获得积分10
4分钟前
4分钟前
4分钟前
对流域发布了新的文献求助10
4分钟前
4分钟前
4分钟前
秦领口发布了新的文献求助30
4分钟前
泡面小猪发布了新的文献求助10
4分钟前
秦领口完成签到,获得积分20
5分钟前
活力鸿发布了新的文献求助10
5分钟前
思源应助科研通管家采纳,获得10
5分钟前
可久斯基完成签到 ,获得积分10
5分钟前
爆米花应助wenwen采纳,获得10
6分钟前
6分钟前
wenwen发布了新的文献求助10
6分钟前
6分钟前
wenwen完成签到,获得积分10
7分钟前
xiaolang2004完成签到,获得积分10
7分钟前
7分钟前
高分求助中
Sustainability in Tides Chemistry 2800
The Young builders of New china : the visit of the delegation of the WFDY to the Chinese People's Republic 1000
Rechtsphilosophie 1000
Bayesian Models of Cognition:Reverse Engineering the Mind 888
Le dégorgement réflexe des Acridiens 800
Defense against predation 800
Very-high-order BVD Schemes Using β-variable THINC Method 568
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3137011
求助须知:如何正确求助?哪些是违规求助? 2787960
关于积分的说明 7784128
捐赠科研通 2444060
什么是DOI,文献DOI怎么找? 1299643
科研通“疑难数据库(出版商)”最低求助积分说明 625497
版权声明 600989